The safety of placental mesenchymal stem cell therapy for the treatment of type 1 diabetes mellitus

Phase 1

Recruiting

• Conditions: Diabetes Mellitus type 1.; Type 1 diabetes mellitus without complications; E10.9

• Registration Number: IRCT20171021036903N2
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

both gender
12-18 years old
type one diabetes mellitus
at least one positive auto antibody of T1DM
in first 6 month of diagnosis

Exclusion Criteria

malignancy
simultaneous auto immune disorders
pregnancy
chronic disorder other than diabetes

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Daily insulin requirement. Timepoint: Before intervention and 1,3,6,12 month after intervention. Method of measurement: daily insulin requirement per kilogram weight.;HbA1c. Timepoint: Before and 1,3,6,12 month after intervention. Method of measurement: blood sample.;C peptide level. Timepoint: Before and 1,3,6,12 month after intervention. Method of measurement: blood sample.

Secondary Outcome Measures

Name	Time	Method
ife threatening major side effect. Timepoint: before and 1,3,6 ,12 months after intervention. Method of measurement: physical examination.